Cite

    Milanese, C. et al. (2003). A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Journal of neurology, neurosurgery and psychiatry. 74 (12), pp. 1689-1692. [Online].